Scalper1 News
Biotech startup Coherus BioSciences (CHRS) was down more than 4% Friday after it said late Thursday that its biosimilar version of Amgen’s (AMGN) Neulasta will take longer to test than previously expected. Coherus said that it decided to increase the number of subjects in an immunogenicity study required for approval of CHS-1701, its biosimilar version of Amgen’s white-blood-cell boosting blockbuster. The company did this after seeing a slightly Scalper1 News
Scalper1 News